Published in Prostate on February 15, 2004
Bringing the heavy: carbon ion therapy in the radiobiological and clinical context. Radiat Oncol (2014) 1.03
Review of clinical experience with ion beam radiotherapy. Br J Radiol (2011) 0.91
International Conference on Advances in Radiation Oncology (ICARO): outcomes of an IAEA meeting. Radiat Oncol (2011) 0.89
Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks. Br J Cancer (2014) 0.85
Evolution of advanced technologies in prostate cancer radiotherapy. Nat Rev Urol (2013) 0.84
Carbon ion irradiation of the human prostate cancer cell line PC3: a whole genome microarray study. Int J Oncol (2014) 0.80
The predictive role of ADC values in prostate cancer patients treated with carbon-ion radiotherapy: initial clinical experience at Shanghai Proton and Heavy Ion Center (SPHIC). J Cancer Res Clin Oncol (2016) 0.75
Particle radiation therapy using proton and heavier ion beams. J Clin Oncol (2007) 3.13
HbA1c 5·7-6·4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet (2011) 2.33
Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res (2004) 2.23
Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy. Int J Urol (2014) 2.21
Effect of postmenopausal status and age at menopause on type 2 diabetes and prediabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 17 (TOPICS 17). Diabetes Care (2013) 2.15
Ocular surface changes with applanation contact lens and coupling fluid use after argon laser photocoagulation in noninsulin-dependent diabetes mellitus. Am J Ophthalmol (2004) 2.06
Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol (2007) 2.03
Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys (2004) 1.98
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol (2011) 1.84
The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci (2011) 1.80
New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmology (2007) 1.71
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med (2010) 1.66
Particle radiotherapy for prostate cancer. Int J Urol (2014) 1.65
Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol (2002) 1.63
Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res (2007) 1.61
Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Cancer (2005) 1.58
Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol (2010) 1.57
Local control and recurrence of stage I non-small cell lung cancer after carbon ion radiotherapy. Radiother Oncol (2004) 1.54
Mathematical projection model of visual loss due to fuchs corneal dystrophy. Invest Ophthalmol Vis Sci (2011) 1.53
Cytokeratin 15 can be used to identify the limbal phenotype in normal and diseased ocular surfaces. Invest Ophthalmol Vis Sci (2006) 1.53
Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. Int J Urol (2010) 1.51
Cyclooxygenase-2 impairs treatment effects of radiotherapy for cervical cancer by inhibition of radiation-induced apoptosis. Int J Radiat Oncol Biol Phys (2006) 1.49
Clinical Results of Carbon Ion Radiotherapy at NIRS. J Radiat Res (2007) 1.49
High serum uric acid level and low urine pH as predictors of metabolic syndrome: a retrospective cohort study in a Japanese urban population. Metabolism (2011) 1.48
Outcomes of shockwave lithotripsy for upper urinary-tract stones: a large-scale study at a single institution. J Endourol (2005) 1.47
A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol (2009) 1.47
Carbon ion radiotherapy: clinical experiences at National Institute of Radiological Science (NIRS). J Radiat Res (2010) 1.46
Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas. J Clin Oncol (2002) 1.46
Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci (2007) 1.45
Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: a single institutional retrospective long-term follow-up study. Int J Urol (2010) 1.45
A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci (2004) 1.44
The comparison of solitary topical micafungin or fluconazole application in the treatment of Candida fungal keratitis. Br J Ophthalmol (2010) 1.43
Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol (2009) 1.42
Health-related quality of life after carbon-ion radiotherapy for prostate cancer: a 3-year prospective study. Int J Urol (2013) 1.41
A novel role of the C-terminus of b 0,+ AT in the ER-Golgi trafficking of the rBAT-b 0,+ AT heterodimeric amino acid transporter. Biochem J (2009) 1.41
Tear function and ocular surface findings in premature and term babies. Ophthalmology (2004) 1.41
Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation. Int J Urol (2012) 1.40
The Influence of handling censored data on estimating progression-free survival in cancer clinical trials (JCOG9913-A). Jpn J Clin Oncol (2002) 1.40
Antineoplastic activity of honey in an experimental bladder cancer implantation model: in vivo and in vitro studies. Int J Urol (2003) 1.40
Tissue elasticity imaging for diagnosis of prostate cancer: a preliminary report. Int J Urol (2006) 1.40
MPO-ANCA-positive slowly progressive glomerulonephritis with focal tuft necrosis and crescents. Intern Med (2002) 1.39
Prognostic factors for regression from impaired glucose tolerance to normal glucose regulation in Japanese patients with nonalcoholic fatty liver disease. Intern Med (2014) 1.39
New method to create a vascular arteriovenous fistula in the arm with an endoscopic technique. J Vasc Surg (2002) 1.39
Microkeratome-assisted phacoemulsification. J Cataract Refract Surg (2005) 1.38
Overview of clinical experiences on carbon ion radiotherapy at NIRS. Radiother Oncol (2004) 1.37
Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol (2007) 1.34
Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys (2005) 1.29
Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol (2010) 1.28
The structural characteristics of radiation oncology in Japan in 2003. Int J Radiat Oncol Biol Phys (2005) 1.28
Curative treatment of Stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Radiat Oncol Biol Phys (2007) 1.27
Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiother Oncol (2003) 1.27
Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer (2011) 1.26
Prostate Cancer Working Group report. Jpn J Clin Oncol (2010) 1.25
Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res (2005) 1.25
Results of carbon ion radiotherapy for head and neck cancer. Radiother Oncol (2012) 1.22
ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod Pathol (2010) 1.21
Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol (2011) 1.21
Transforming growth factor-beta promotes survival of mammary carcinoma cells through induction of antiapoptotic transcription factor DEC1. Cancer Res (2007) 1.21
Serum-free spheroid culture of mouse corneal keratocytes. Invest Ophthalmol Vis Sci (2005) 1.20
Habitual intake of lactic acid bacteria and risk reduction of bladder cancer. Urol Int (2002) 1.20
Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer (2003) 1.18
Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol (2010) 1.18
Carbon beam therapy overcomes the radiation resistance of uterine cervical cancer originating from hypoxia. Clin Cancer Res (2006) 1.16
Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer (2012) 1.16
Mucosal malignant melanoma of the head and neck treated by carbon ion radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.16
Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer (2012) 1.15
Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys (2004) 1.14
Carbon-ion radiation therapy for prostate cancer. Int J Urol (2012) 1.13
A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol (2006) 1.13
Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int (2006) 1.12
Real-time elastography for the diagnosis of prostate cancer: evaluation of elastographic moving images. Jpn J Clin Oncol (2009) 1.12
Current pathology keys of renal cell carcinoma. Eur Urol (2011) 1.11
Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction. Ophthalmology (2002) 1.11
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol (2013) 1.10
Association between meibomian gland changes and aging, sex, or tear function. Cornea (2006) 1.10
First clinical experience in carbon ion scanning beam therapy: retrospective analysis of patient positional accuracy. J Radiat Res (2012) 1.09
The impact of real-time tissue elasticity imaging (elastography) on the detection of prostate cancer: clinicopathological analysis. Int J Clin Oncol (2007) 1.09
The role of oxidative stress and inflammation in conjunctivochalasis. Invest Ophthalmol Vis Sci (2009) 1.09
Disruptive effect of chloroquine on lysosomes in cultured rat hepatocytes. Biol Pharm Bull (2005) 1.09
Effects of carbon ion beam on putative colon cancer stem cells and its comparison with X-rays. Cancer Res (2011) 1.09
Comparison of efficacy and toxicity of short-course carbon ion radiotherapy for hepatocellular carcinoma depending on their proximity to the porta hepatis. Radiother Oncol (2010) 1.08
Examination of GyE system for HIMAC carbon therapy. Int J Radiat Oncol Biol Phys (2006) 1.08
Immunologic effects of perinatal exposure to dioxins, PCBs and organochlorine pesticides in Japanese infants. Chemosphere (2007) 1.08